Received: from DU7PR01CA0025.eurprd01.prod.exchangelabs.com (2603:10a6:10:50e::15) by DB9PR02MB9780.eurprd02.prod.outlook.com (2603:10a6:10:451::6) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.292.25; Wed, 12 Aug 2026 13:53:24 +0000 Received: from DB1PEPF00039234.eurprd03.prod.outlook.com (2603:10a6:10:50e:cafe::a4) by DU7PR01CA0025.outlook.office365.com (2603:10a6:10:50e::15) with Microsoft SMTP Server (version=TLS1_3, cipher=TLS_AES_256_GCM_SHA384) id 15.21.315.13 via Frontend Transport; Wed, 12 Aug 2026 13:53:24 +0000 Received: from mail1.rit.ee (213.184.53.4) by DB1PEPF00039234.mail.protection.outlook.com (10.167.8.107) with Microsoft SMTP Server (version=TLS1_3, cipher=TLS_AES_256_GCM_SHA384) id 15.21.315.6 via Frontend Transport; Wed, 12 Aug 2026 13:53:24 +0000 Received: from DB9PR02MB9780.eurprd02.prod.outlook.com (2603:10a6:10:451::6) by DB9PR02MB7817.eurprd02.prod.outlook.com with HTTPS; Wed, 12 Aug 2026 13:53:29 +0000 Received: from [90.190.15.138] (Authenticated sender: info@epal.ee) by MTA-244-111.TLL07.ZONEAS.EU (ZoneMTA Forwarder) with API id 19ff63fa3eb0002cc1.014 for ; Wed, 12 Aug 2026 13:53:13 +0000 From: Subject: =?utf-8?Q?Eesti_Proviisorapteekide_Liidu_k?= =?utf-8?Q?onverents_=E2=80=9EApteek_esmatasandi_ee?= =?utf-8?Q?sliinil=E2=80=9C_-_9._septembril_Tallinn?= =?utf-8?Q?as?= Date: Wed, 12 Aug 2026 16:53:18 +0300 Keywords: ly Message-ID: <30d97708-285d-f089-9507-f44b52be364c@epal.ee> MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_0019_01DD2B10.8FEF5200" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQFIzTIkNiTcPfuXfIyivHlKrp2hSw== Authentication-Results: spf=fail (sender IP is 213.184.53.4) smtp.mailfrom=epal.ee; dkim=pass (signature was verified) header.d=epal.ee;dmarc=bestguesspass action=none header.from=epal.ee;compauth=pass reason=109 x-ms-traffictypediagnostic: DB1PEPF00039234:EE_|DB9PR02MB9780:EE_|DB9PR02MB7817:EE_ X-MS-Office365-Filtering-Correlation-Id: a6f00cb4-c340-4090-e687-08def87913f8 X-MS-Exchange-AtpMessageProperties: SA|SL X-MS-Exchange-Transport-CrossTenantHeadersStamped: DB9PR02MB9780 X-MS-Exchange-Organization-ExpirationStartTime: 12 Aug 2026 13:53:24.2999 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Network-Message-Id: a6f00cb4-c340-4090-e687-08def87913f8 X-EOPAttributedMessage: 0 X-MS-Exchange-Organization-MessageDirectionality: Incoming X-MS-Exchange-Organization-AuthAs: Anonymous X-MS-Exchange-Organization-AuthSource: DB1PEPF00039234.eurprd03.prod.outlook.com X-MS-Exchange-Organization-SCL: -1 X-MS-PublicTrafficType: Email X-Microsoft-Antispam: BCL:0;ARA:13230040|82310400026|19092799006|13003099007|55112099003|16102099003|19002099009|10067099003|11063799006|56012099006|5063699009|8096899003|18003699003|43540500003; X-Forefront-Antispam-Report: CIP:213.184.53.4;CTRY:EE;LANG:et;SCL:-1;SRV:;IPV:CAL;SFV:NSPM;H:mail1.rit.ee;PTR:mail1.rit.ee;CAT:NONE;SFS:(13230040)(82310400026)(19092799006)(13003099007)(55112099003)(16102099003)(19002099009)(10067099003)(11063799006)(56012099006)(5063699009)(8096899003)(18003699003)(43540500003);DIR:INB; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 12 Aug 2026 13:53:24.1443 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: a6f00cb4-c340-4090-e687-08def87913f8 X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-AuthAs: Anonymous X-MS-Exchange-CrossTenant-AuthSource: DB1PEPF00039234.eurprd03.prod.outlook.com X-MS-Exchange-CrossTenant-FromEntityHeader: Internet X-MS-Exchange-Transport-EndToEndLatency: 00:00:04.9707606 X-MS-Exchange-Processed-By-BccFoldering: 15.21.0315.000 X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(4710232)(4717077)(4999285)(920097)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: =?us-ascii?Q?l46F/WM4H1wGzt/gHrP3STUGUQiy5Xv3tzapC9bs6kgON38Qaxvke69H1QH6?= =?us-ascii?Q?WyKhfk7QNvBkk6wF0i9elnhd/ReMWZdfR5rsMBnGHGip3eafTz0q862RCBNT?= =?us-ascii?Q?+QIoegu1VUsccD9Bsc0Fv+M7OpAD+P5GRYU0urVXYWwB5GvbkiaGUKhdQMN+?= =?us-ascii?Q?iCKsfyB2Pj5fwiH07kcJzQZC2O+cx5jcRHIXFALaWMj8k4nS6eLFwAsH7ZKc?= =?us-ascii?Q?URtbN2FQIWxcienHl55udU7C8wZYEyawCW6UnGtxMmrCqIBep3P2G9OJI3a3?= =?us-ascii?Q?CaZF8QM/8SpOGLPjiIsZFbimSqz4w7G2NTpgJJjeuLVyXlXkRShHZpDbmwVI?= =?us-ascii?Q?B1A2o/2dWmxtdqyEBGXT2DOjaNECsyDJUc/qcZbPvULQbKD0LnkeJf1pCy03?= =?us-ascii?Q?AQi3wll0h//X2a+fyfXcH2if0FTJHT7+oYC2yLBOrIh7xz38kJcd4ESPSsqn?= =?us-ascii?Q?vSEQ7ShBbpXe54C/WQyQklKyIynGzzGVa3eFC7E2glBImYdagNsRQSjzNyFD?= =?us-ascii?Q?Mksjy51o2oAplXJUY6tYt6Rxk7k2XI5+aR1tN6BwoO71l2ugtQapWUgtQoIE?= =?us-ascii?Q?WenoX7hG1Weo4ZEXSOdyB1kfa7AEh2zneo2E56wRlawvRVQGknFxpkO1wcKE?= =?us-ascii?Q?m5Wux7+Y38dRYQ0bppAjLpvqfRrui8b9+PEzJEHMg0/F4V/iA3oeR8HJkN3/?= =?us-ascii?Q?U6ID4eMokj1dAStscHZfwzo6FRYKlPKwt3urHeANFWfjVvIi3u5 jBbDq3kqx?= =?us-ascii?Q?+b4od7M2Tc0uJr/QWTV0xrjKKbhVHonIqEecGbpkAVKgM4OBbgEvAq07VVBw?= =?us-ascii?Q?ygqBqNYtJ8sIip/1X6qVpZfmfaayEFu0703q205ejEKeHhVYMduK7uolpNGf?= =?us-ascii?Q?0qbu4Z1rX5mgYfFmX1BaEqnCd3U71o4Qbt4f00KaPYahRoKHygsTUMOKF76o?= =?us-ascii?Q?kh34NSluJhT9tw+aJtF2os77VUWO1vMFAcz/4tUHZCf2nisehAT41eo8lARB?= =?us-ascii?Q?xulQpOb+0+OpXR9Atsm96kw3IL5odJG1sAut5Zc2rPWUI0Blk9TfUNVyGf5l?= =?us-ascii?Q?Yqh75N0ym2CebHTOtOzkRYmzOHYMoHNy1ZBup6ywKuM+NWqZhi+sDVEr413v?= =?us-ascii?Q?5XpIFXj/IeXbQJ7DjDtMeHtsnd7bJpKm0DlkRpI0n+bsxOpN1Clv3PNw18Vb?= =?us-ascii?Q?nCBNZhgonSAiiH9jVl/5JyaLMBt6iuipvVOzjxcmaU+Sb4bcyDxLQY6+fnJy?= =?us-ascii?Q?/warDk9XXcI4VUi90zA1q6thZmuhRVafmDG41iVtjI8ppin5W1G4FWhsNCCY?= =?us-ascii?Q?pTHavBcJShBn5k8g1I8Y99SxwDedh+ZhBp4RAxJ3hQuU+VkR0QO/pK8JULkr?= =?us-ascii?Q?7lxrrukVYfxX3+gqDo/9OdPUR+m4Xug5H9WrVgLDCLIlxh4JpBbWudyGOwAp?= =?us-ascii?Q?PgBsERn5a8vGNmJ4x0c4GXNk7xvNKbXFmW6vH9djrXaTKTJjO+FyeI9JV/bY?= =?us-ascii?Q?DcYAUB/s8kHVpRQpTb6XmuZQtYf0n8L6QvztU pDC7nAb6qGxyGuxYDflGayR?= =?us-ascii?Q?5CCfdUUz8iEwEZjZEWb2UWZpHtFa0r/IF4JrQ0dIaTzC6bIfn/1a3Ne40fcO?= =?us-ascii?Q?oOwUX1LxQX5V1jM3sC5UIDuotxqgV2PfY/3YyMxOEG2RkrcZWCaRE5IBLCl6?= =?us-ascii?Q?Fzpn9MWAattxir3hWTiQ7UV0xeJjnwyzTEgiOHG2uD0r3f2puCdhkMEHYW6T?= =?us-ascii?Q?0EQUHy+HDmO0NP2qCSROvoiJRikmRxn+Z3ChlhkKHcRS7GDqTxAC1KA7I0oy?= =?us-ascii?Q?X54/i+wKTtd5ub25+hzRgS57qctP9itMAyo35wvq0mADmgCs3u5Sr+erflN1?= =?us-ascii?Q?Zd9LyyKyCUf+RDp5+pihIDXFYb5yHXQQp156VmfC+32reQEWRzRNUq14FC77?= =?us-ascii?Q?KEJ8qk+tEoHDNzWawnky6VD3ess6aza8ZPfnbSrzVLXwdrmLxWg7CvHUnN3O?= =?us-ascii?Q?JW+nbFrgeNiWu0u0kc3e3mjlavijI4kzT24QZYaMyT8GdQha8fvZrWGBPJEI?= =?us-ascii?Q?u6tf3wRdnKIT4OIqwhJhbm63X3BT/6pcS8lP7BDWcG2JcJpbEGAlQPXdZRyG?= =?us-ascii?Q?rIBbLkfMoYf3UnGyKQG0F4FimXkK9sHD4shtF3CQeOjVkmvkO3xE3gspD8du?= =?us-ascii?Q?BGG/RH1FPqgJtCI95o5C8IhK84kdOCdewse7eVZkNBmlTOHEPr2zTlTR9VLl?= =?us-ascii?Q?ew4N8btRxd1QqI2nat82wsNKjKSld5D05/qsGchNkzi4Lc2p7+GVw+Oaa7Gn?= =?us-ascii?Q?gpwzJR78ZJFOElmksrxopOc TnlCfrzamJ71Mypv7S6pEN9NE1/q5KBmGnmcR?= =?us-ascii?Q?ORTqQIwyXjixHWwG7IpT1bjNd3UagKPW4FqS4zDCW8UskE11/vHT1AXW33VB?= =?us-ascii?Q?82UrMPMyU4BG/hOWh6kHdSivOTx8RQCLM4cc61sn8yXhgs4m4dZetOdxL0ME?= =?us-ascii?Q?fhA86fSK7PUxuGoicrvh79AXjqARHTGTe56+JZ9/K9A7LW09hdugDrHRQb9b?= =?us-ascii?Q?Z7XGP1Y8eRH+P65YRpnm5me3BJTa/qh5aNYQbMMe+elRr5yW19ICRAJcvpN0?= =?us-ascii?Q?qz5bP0Veh6CdmAmcZtBiuiMnp4jYkz3fBmftg55cghipEo5Jsw7VsI1qPWYj?= =?us-ascii?Q?ctoaiFzjpS1oX1OH+CYkt9yFw6YkKBZqxowZWTaUNAR4Ws+INkQ0esi5QTGD?= =?us-ascii?Q?yGCPCLhm8yiBA1zo+TWq5Bgw9+QeCB0eN9OFu13eRRI8dDHhR7HQKtsAwano?= =?us-ascii?Q?nXmWxnElC5OPZtDgb6pLLi5EwPWBQ+OA5dscuHM7wNobCnsGxe3Keb+DRTXK?= =?us-ascii?Q?Hbdf0qNxK24m3Vlg2HAVFiwA4bN4HIl7gHt5lyI=3D?= Content-Language: en-us received-spf: Pass (mail1.rit.ee: domain of postmaster@MTA-244-111.TLL07.ZONEAS.EU designates 85.234.244.111 as permitted sender) identity=helo; client-ip=85.234.244.111; receiver=mail1.rit.ee; envelope-from="info@epal.ee"; x-sender="postmaster@MTA-244-111.TLL07.ZONEAS.EU"; x-conformance=spf_only; x-record-type="v=spf1"; x-record-text="v=spf1 ip4:217.146.64.0/20 ip4:185.31.240.0/22 ip4:85.222.232.0/22 ip4:85.234.242.0/23 ip4:85.234.244.0/22 ip6:2a02:29e8::/29 ip4:90.191.225.240/29 ip6:2001:7d0:d100:6::/64 ip4:90.191.225.208/28 ip4:87.119.168.48/29 ip4:217.68.24.144/29 ip4:45.151.4.0/23 -all" x-ms-exchange-organization-originalclientipaddress: 213.184.53.4 x-ms-exchange-organization-originalserveripaddress: 10.167.8.107 X-OlkEid: 0000000033F4068251E5764083FB7241D8AC8008070034AD76187591974DBF6C4F76951C873A0100020000000000EE036A86AA193F47AA713E32FE8F2E570000000012F000001C9263A25E0A2241BE0758DB2D9AF9E9 X-CSE-ConnectionGUID: c5pgUihVSvOG/otMpsR0Dg== X-CSE-MsgGUID: fbLnMTqgR5K2hzv80ADyTA== X-ThreatScanner-Verdict: Negative X-IPAS-Result: =?us-ascii?q?A0FVAwByeXxqe2/06lVahBaBBIEKXjQHCB4rhFiDT41xh?= =?us-ascii?q?HGUAodcDwEBAQEBAUMaBAEBAwEDhH4kjUcBHwYBOBMBAgQDAgMBAQEBAQEBA?= =?us-ascii?q?QEBAQsBAQEEAQEBAgEBAgQDAQEBAQIQAQFCSYZPDYJFGTiCFiyBAjIdAQEvC?= =?us-ascii?q?Rg9BwKBTIInAYIkBEwHp1mcHIEygQGCDAEBBoEI20GBUgMGgU2IXQGBXwECh?= =?us-ascii?q?AYQgk2CcYINgRUnC4gngy4WglSCJnoSgmOBeY9oIgMmgUgXEoFrA3sLbTMZB?= =?us-ascii?q?IF4NVgbglCDI4MBgxWBIoEggiQChCVeAR4LbT03CSiPOyCDf1DIYZBJlT8GD?= =?us-ascii?q?wQvl2eTBYgEiyeTZ5tvgUkjgVyCXgmBQB8xAxkPji0WHIQwyy1HMj0BAQIFA?= =?us-ascii?q?gcBCwEBAwkCgVQUkDSBTAE?= X-Talos-CUID: 9a23:rwGdBWDIALfqtpr6EyI67EEpG8AbSWP64zDXP2qgElwxZLLAHA== X-Talos-MUID: 9a23:VCyragqGDh8i+8ba7Awezz9oEMFN372hMh0uy5UUpZncHABhBx7I2Q== X-IronPort-Anti-Spam-Filtered: true X-IronPort-AV: E=Sophos;i="6.25,219,1779138000"; d="scan'208";a="77332558" X-Amp-Result: SKIPPED(no attachment in message) X-Amp-File-Uploaded: False X-EOPTenantAttributedMessage: 8fe098d2-428d-4bd4-9803-7195fe96f0e2:0 dkim-signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=epal.ee; q=dns/txt; s=zone; bh=yEXwoYFnDT1f8jz4Pu2fHvniTXThPPImSqeHGJhvkcI=; h=from:subject:date:message-id:mime-version:content-type; b=XYMKbKceIS+00xELZH4pev8M8qPY+1+qtI3YNDW4HupK3N/Vd4bYobztpJkiFLB+eZK1LBJWL k74I9i7soYp8SO4aBlls1hutIpvFSwlucuz+Oq5vInjcel44kgkZ4CRnC2EQQK79CmykDDj7RMT IHcNzxphXHdIL533msufMjaifwYZQUb+PRSgldfKxPJgjb83arB1YbO73l4behaoxAGnph08wcN L3MWpXQEOKNyQ9XV3fApRxmN+g9W9J0aKbaHbsdbHkqaHVXptVefokD0aomZ303qHb8O73xv2bn j6HMhMG/1OmjPbMe0l/3NjViH6/IzduFxlu9DU7A6HXA== X-Ironport-Dmarc-Check-Result: validskip X-DisclaimerOO: 1 user-agent: Zone Webmail 3.10.7 This is a multipart message in MIME format. ------=_NextPart_000_0019_01DD2B10.8FEF5200 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Hea koostööpartner Kutsume Teid osalema Eesti Proviisorapteekide Liidu konverentsil „Apteek esmatasandi eesliinil“. Konverents toimub 9. septembril Tallinnas Swissôtel konverentsikeskuses (Tornimäe 3). Sel aastal on EPAL konverentsil peamisteks teemadeks apteegi teenuse tulevik, kvaliteet ja toimepidevus. Oleme kutsunud konverentsile esinema oma valdkonna parimaid tippspetsialiste nii Eestist kui välismaalt, et mõelda veidi laiemalt ning arutleda üheskoos, kuidas pakkuda inimesele parimat apteegiteenust, käies arengute ning muutustega ühte sammu. Selle aasta konverentsil tutvustame uut apteegi kvaliteedijuhendit ning arutame, kas esmatasand on kriisideks valmis. Eesti Proviisorapteekide Liit (EPAL) on Eesti suurim apteeke ühendav organisatsioon, mille liikmeteks on 317 apteeki ja 1206 apteekrit üle Eesti. EPAL pakub tipptasemel partnerlust riigile ja tervishoiusektori osapooltele. Link registreerimisele ja täpsem programm: https://epal.ee/konverents Ootame Teid osalema ja kaasa mõtlema! Tervitades Ly Rootslane Juhatuse liige Eesti Proviisorapteekide Liit 5886 3915 ------=_NextPart_000_0019_01DD2B10.8FEF5200 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable

T=C3=A4helepanu! Tegemist on v=C3=A4lisv=C3=B5rgust saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte = avada.

Hea koost=C3=B6=C3=B6partner

Kutsume Teid osalema Eesti = Proviisorapteekide = Liidu konverentsil =E2=80=9EApteek esmatasandi eesliinil=E2=80=9C. 

Konverents toimub 9. septembril = Tallinnas Swiss=C3=B4tel = konverentsikeskuses (Tornim=C3=A4e = 3).

 

Sel aastal on EPAL konverentsil peamisteks teemadeks apteegi teenuse = tulevik, kvaliteet ja toimepidevus.

Oleme kutsunud konverentsile esinema oma = valdkonna parimaid tippspetsialiste nii Eestist kui v=C3=A4lismaalt, et = m=C3=B5elda veidi laiemalt ning arutleda =C3=BCheskoos, kuidas pakkuda inimesele parimat apteegiteenust, k=C3=A4ies arengute ning muutustega = =C3=BChte sammu. Selle aasta konverentsil tutvustame uut apteegi = kvaliteedijuhendit ning arutame, kas esmatasand on kriisideks = valmis. 

 

Eesti Proviisorapteekide Liit (EPAL) on Eesti = suurim apteeke =C3=BChendav  organisatsioon, 

mille liikmeteks on 317 apteeki ja = 1206 apteekrit =C3=BCle Eesti. EPAL pakub tipptasemel partnerlust

riigile ja tervishoiusektori osapooltele.

 

Link registreerimisele ja t=C3=A4psem = programm: https://epal.ee/konverents=

 

Ootame Teid osalema ja kaasa = m=C3=B5tlema!

Tervitades

Ly Rootslane

Juhatuse liige

Eesti Proviisorapteekide Liit

5886 3915

------=_NextPart_000_0019_01DD2B10.8FEF5200--